2 MAR 2016 | Alteogen set to start phase I testing for Herceptin biosimilar
Health Canada approved a phase I trial for Alteogen’s ALT02, a biosimilar version of trastuzumab
12 OCT 2015 | Alteogen inks deal with 3Sbio for ADC targeting HER2
A novel ADC targeting HER2 pathways based on Alteogen's NexMab ADC technology.
13 JUL 2015 | The patent for long-acting recombinant Alpha-1 Antitrypsin (A1AT)
ALTEOGEN succeeded in registering the patent for long-acting recombinant Alpha-1 Antitrypsin (A1AT) in US.
30 MAR 2015 | The project with KISSEI has been progressing steadily
The cooperation project between KISSEI and ALTEOGEN has been progressing steadily.
12 DEC 2014 | ALTEOGEN is listed on KOSDAQ
ALTEOGEN (KOSDAQ:196170) is started to be traded in Korean stock market, KOSDAQ on 12th Dec. 2014.